PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RXT vs. SYRE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RXT and SYRE is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

RXT vs. SYRE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rackspace Technology, Inc. (RXT) and Spyre Therapeutics Inc. (SYRE). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
20.34%
-16.59%
RXT
SYRE

Key characteristics

Sharpe Ratio

RXT:

0.68

SYRE:

-0.04

Sortino Ratio

RXT:

1.34

SYRE:

0.44

Omega Ratio

RXT:

1.17

SYRE:

1.05

Calmar Ratio

RXT:

0.52

SYRE:

-0.03

Martin Ratio

RXT:

2.71

SYRE:

-0.08

Ulcer Index

RXT:

18.24%

SYRE:

35.55%

Daily Std Dev

RXT:

72.69%

SYRE:

71.04%

Max Drawdown

RXT:

-95.86%

SYRE:

-99.12%

Current Drawdown

RXT:

-88.88%

SYRE:

-92.90%

Fundamentals

Market Cap

RXT:

$664.39M

SYRE:

$1.28B

EPS

RXT:

-$3.84

SYRE:

-$37.90

Total Revenue (TTM)

RXT:

$2.05B

SYRE:

$0.00

EBITDA (TTM)

RXT:

-$441.50M

SYRE:

-$147.31M

Returns By Period

In the year-to-date period, RXT achieves a 31.22% return, which is significantly higher than SYRE's -8.55% return.


RXT

YTD

31.22%

1M

12.84%

6M

20.33%

1Y

47.96%

5Y*

N/A

10Y*

N/A

SYRE

YTD

-8.55%

1M

-2.38%

6M

-16.61%

1Y

-9.71%

5Y*

-35.23%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RXT vs. SYRE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXT
The Risk-Adjusted Performance Rank of RXT is 6868
Overall Rank
The Sharpe Ratio Rank of RXT is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of RXT is 6767
Sortino Ratio Rank
The Omega Ratio Rank of RXT is 6666
Omega Ratio Rank
The Calmar Ratio Rank of RXT is 6868
Calmar Ratio Rank
The Martin Ratio Rank of RXT is 7171
Martin Ratio Rank

SYRE
The Risk-Adjusted Performance Rank of SYRE is 4444
Overall Rank
The Sharpe Ratio Rank of SYRE is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of SYRE is 4444
Sortino Ratio Rank
The Omega Ratio Rank of SYRE is 4343
Omega Ratio Rank
The Calmar Ratio Rank of SYRE is 4545
Calmar Ratio Rank
The Martin Ratio Rank of SYRE is 4444
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RXT vs. SYRE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Rackspace Technology, Inc. (RXT) and Spyre Therapeutics Inc. (SYRE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RXT, currently valued at 0.68, compared to the broader market-2.000.002.000.68-0.04
The chart of Sortino ratio for RXT, currently valued at 1.34, compared to the broader market-4.00-2.000.002.004.006.001.340.44
The chart of Omega ratio for RXT, currently valued at 1.17, compared to the broader market0.501.001.502.001.171.05
The chart of Calmar ratio for RXT, currently valued at 0.52, compared to the broader market0.002.004.006.000.52-0.03
The chart of Martin ratio for RXT, currently valued at 2.71, compared to the broader market-10.000.0010.0020.0030.002.71-0.08
RXT
SYRE

The current RXT Sharpe Ratio is 0.68, which is higher than the SYRE Sharpe Ratio of -0.04. The chart below compares the historical Sharpe Ratios of RXT and SYRE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
0.68
-0.04
RXT
SYRE

Dividends

RXT vs. SYRE - Dividend Comparison

Neither RXT nor SYRE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RXT vs. SYRE - Drawdown Comparison

The maximum RXT drawdown since its inception was -95.86%, roughly equal to the maximum SYRE drawdown of -99.12%. Use the drawdown chart below to compare losses from any high point for RXT and SYRE. For additional features, visit the drawdowns tool.


-92.00%-90.00%-88.00%-86.00%-84.00%SeptemberOctoberNovemberDecember2025February
-88.88%
-91.34%
RXT
SYRE

Volatility

RXT vs. SYRE - Volatility Comparison

Rackspace Technology, Inc. (RXT) has a higher volatility of 19.62% compared to Spyre Therapeutics Inc. (SYRE) at 13.39%. This indicates that RXT's price experiences larger fluctuations and is considered to be riskier than SYRE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
19.62%
13.39%
RXT
SYRE

Financials

RXT vs. SYRE - Financials Comparison

This section allows you to compare key financial metrics between Rackspace Technology, Inc. and Spyre Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab